The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of approximately 5.9% of Tandem Diabetes Care, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Both reporting persons each disclosed aggregate beneficial ownership of 4,091,935.35 shares of Tandem Diabetes Care common stock.
  • Percent of class: The aggregate amount represents 5.9% of Tandem Diabetes Care's outstanding common stock.
  • Shared voting power: Both entities reported shared voting power over 4,082,859.35 shares, with sole voting power of 0.00.
  • Shared dispositive power: Both entities reported shared dispositive power over 4,082,936.35 shares, with sole dispositive power of 0.00.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Filing signed: The statement was signed by Ameen Soetan, attorney-in-fact for both entities, dated October 8, 2026.
  • Ordinary course certification: The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Goldman Sachs Crosses 5% Ownership Threshold in Tandem Diabetes Care

According to the Schedule 13G filed jointly by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, the two entities together beneficially own 4,091,935.35 shares of common stock, par value $0.001 per share, in Tandem Diabetes Care, Inc. (CUSIP: 875372203), representing 5.9% of the class. The event triggering the filing occurred on September 30, 2026, and the statement was dated October 8, 2026.

The filing discloses that neither entity holds any sole voting or sole dispositive power over the reported shares. Instead, both The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC each report shared voting power of 4,082,859.35 shares and shared dispositive power of 4,082,936.35 shares. As disclosed in the filing's Exhibit 99.2, the securities reported by The Goldman Sachs Group, Inc. as a parent holding company "are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC," described as a broker-dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, and a subsidiary of GS Group.

Exhibit 99.3 of the filing notes that the disclosure "reflects the securities beneficially owned by certain operating units (collectively, the 'Goldman Sachs Reporting Units') of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates." The Goldman Sachs Reporting Units disclaim beneficial ownership of securities held in certain client accounts and certain investment entities, to the extent interests are held by persons other than the Goldman Sachs Reporting Units, according to the filing.

What Was Disclosed

Goldman Sachs Group and Goldman Sachs & Co. LLC jointly filed a Schedule 13G reporting 4,091,935.35 shares, equal to 5.9% of Tandem Diabetes Care common stock, as of September 30, 2026, with no sole voting or dispositive power claimed.